Tuesday, July 8, 2025 7/8/2025

Gyrate Atrophy Ocular and Systemic Study (GYROS)

Award Number: R01FD007628
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2022
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Gyrate Atrophy Ocular and Systemic Study (GYROS) - 1 Project Summary/Abstract for GYROS 2 Gyrate atrophy is a rare inherited chorioretinal degeneration that is associated with 3 hyperornithinemia caused by autosomal recessive mutations in the ornithine aminotransferase 4 (OAT) gene and leads to severe loss of vision. The current standard of care treatment is a 5 highly burdensome arginine-restricted diet (ARD) fraught with management complications. The 6 principal investigators are currently developing a gene augmentation therapy, a potential 7 treatment strategy that may preserve or improve vision while avoiding or reducing the 8 need for ARD. To facilitate a future interventional clinical trial, there is a need to characterize 9 the natural history of OAT-related ocular and systemic disease progression. The study aims are: 10 1. Natural History – Characterize the natural history of ornithine levels and retinal 11 degeneration (RD) associated with disease-causing OAT variants in the presence of 12 standard dietary treatment regimens over 4 years, using metabolic measures of fasting 13 plasma and blood spot amino acids panels, functional and structural measures of RD, 14 and patient-reported outcome measures. 15 2. Metabolic-Structure-Function Relationships – Explore the relationships between 16 structural and functional RD outcome measures and plasma ornithine levels. 17 3. Identify Rapid Progressors – Explore the relationship of possible risk factors 18 (genotype, phenotype, environmental, standard care dietary regimen) with severity and 19 progression of outcome measures. 20 This natural history study will inform the future interventional clinical trial design as follows: 21  Determine within-patient variability of ornithine levels 22  Develop quantitative measures of progression of the area of preserved retina and 23 establish its reproducibility, sensitivity to change, and relationship with other measures 24  Establish rates of progression of functional RD, structural RD, and patient-reported 25 outcome measures, and determine which measures are most sensitive to change 26  Determine primary time points and duration for a planned future treatment trial 27  Use variability and inter-eye correlation of outcomes for trial sample size calculations 28  Identify candidates for the future trial, including eligibility criteria based on risk factors 29 and cut points for severity of disease most likely to benefit from treatment 30  Establish study procedures and workflows


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	001	2	3/25/2025	NON-COMPETING CONTINUATION	$0
2025	2024	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	000	2	3/21/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $400,000 )
2024	2024	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	000	2	8/5/2024	NON-COMPETING CONTINUATION	$400,000
2024	2024	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	001	2	8/6/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $400,000

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	000	1	11/1/2022	NEW	$0
2023	2022	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	002	1	8/30/2023	NEW	$0
2023	2022	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	001	1	8/9/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $400,000 )
2022	2022	JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC.	15310 AMBERLY DR STE 350	TAMPA	FL	33647	HILLSBOROUGH	USA	Food and Drug Administration Research	000	1	9/8/2022	NEW	$400,000
														Subtotal = $400,000

Grand Total All Awards = $800,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gyrate Atrophy Ocular and Systemic Study (GYROS)

Award Number: R01FD007628

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2022

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer